State of New Jersey Common Pension Fund D Buys 326 Shares of Repligen Corporation $RGEN

State of New Jersey Common Pension Fund D increased its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 1.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,252 shares of the biotechnology company’s stock after acquiring an additional 326 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Repligen were worth $2,270,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of RGEN. Twin Tree Management LP bought a new stake in Repligen in the 1st quarter valued at $29,000. Signaturefd LLC grew its holdings in shares of Repligen by 65.3% in the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 128 shares during the last quarter. AlphaQuest LLC bought a new stake in shares of Repligen in the 2nd quarter worth about $104,000. GAMMA Investing LLC grew its holdings in shares of Repligen by 40.1% in the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 274 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Repligen in the 1st quarter worth about $132,000. Institutional investors own 97.64% of the company’s stock.

Insiders Place Their Bets

In other news, Director Martin D. Madaus bought 1,800 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $112.13 per share, with a total value of $201,834.00. Following the completion of the purchase, the director owned 1,800 shares of the company’s stock, valued at $201,834. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.20% of the company’s stock.

Repligen Price Performance

NASDAQ RGEN opened at $151.57 on Wednesday. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $182.52. The business has a 50 day simple moving average of $133.89 and a 200 day simple moving average of $128.45. The stock has a market cap of $8.53 billion, a price-to-earnings ratio of -606.26, a PEG ratio of 3.56 and a beta of 1.08. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company’s revenue was up 21.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.43 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on RGEN. Stephens raised shares of Repligen to an “overweight” rating and set a $160.00 target price on the stock in a report on Tuesday, July 22nd. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $205.00 target price on shares of Repligen in a report on Tuesday, September 2nd. Hsbc Global Res upgraded shares of Repligen to a “strong-buy” rating in a research report on Wednesday, October 1st. Wells Fargo & Company reduced their price target on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 30th. Finally, Jefferies Financial Group set a $160.00 price target on shares of Repligen and gave the stock a “hold” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $171.54.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.